Literature DB >> 32500705

Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.

Anvesh K R Dasari1, Jenette Arreola1, Brian Michael2, Robert G Griffin2, Jeffery W Kelly3, Kwang Hun Lim1.   

Abstract

Amyloid formation of full-length TTR involves dissociation of the native tetramers into misfolded monomers that self-assemble into amyloid. In addition to the full-length TTR, C-terminal fragments including residues 49-127 were also observed in vivo, implying the presence of additional misfolding pathways. It was previously proposed that a proteolytic cleavage might lead to the formation of the C-terminal fragment TTR amyloid. Here, we report mechanistic studies of misfolding and aggregation of a TTR variant (G53A) in the absence and presence of a serine protease. A proteolytic cleavage of G53A in the CD loop (K48 and T49) with agitation promoted TTR misfolding and aggregation, suggesting that the proteolytic cleavage may lead to the aggregation of the C-terminal fragment (residues 49-127). To gain more detailed insights into TTR misfolding promoted by proteolytic cleavage, we investigated structural changes in G53A TTR in the presence and absence of trypsin. Our combined biophysical analyses revealed that the proteolytic cleavage accelerated the formation of spherical small oligomers, which exhibited cytotoxic activities. However, the truncated TTR appeared to maintain native-like structures, rather than the C-terminal fragment (residues 49-127) being released and unfolded from the native state. In addition, our solid-state nuclear magnetic resonance and Fourier transform infrared structural studies showed that the two aggregates derived from the full-length and cleaved TTR exhibited nearly identical molecular structural features, suggesting that the proteolytic cleavage in the CD loop destabilizes the native tetrameric structure and accelerates oligomer formation through a common TTR misfolding and aggregation mechanism rather than through a distinct molecular mechanism.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32500705      PMCID: PMC7339286          DOI: 10.1021/acs.biochem.0c00079

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  53 in total

1.  Probability-based protein secondary structure identification using combined NMR chemical-shift data.

Authors:  Yunjun Wang; Oleg Jardetzky
Journal:  Protein Sci       Date:  2002-04       Impact factor: 6.725

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils.

Authors:  Giorgia Zandomeneghi; Mark R H Krebs; Margaret G McCammon; Marcus Fändrich
Journal:  Protein Sci       Date:  2004-11-10       Impact factor: 6.725

4.  Fibril in senile systemic amyloidosis is derived from normal transthyretin.

Authors:  P Westermark; K Sletten; B Johansson; G G Cornwell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

5.  The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution.

Authors:  J A Hamilton; L K Steinrauf; B C Braden; J Liepnieks; M D Benson; G Holmgren; O Sandgren; L Steen
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

6.  Trans-suppression of misfolding in an amyloid disease.

Authors:  P Hammarström; F Schneider; J W Kelly
Journal:  Science       Date:  2001-09-28       Impact factor: 47.728

7.  Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.

Authors:  A Gustavsson; H Jahr; R Tobiassen; D R Jacobson; K Sletten; P Westermark
Journal:  Lab Invest       Date:  1995-11       Impact factor: 5.662

8.  Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Authors:  Per Hammarström; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Science       Date:  2003-01-31       Impact factor: 47.728

9.  Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award.

Authors:  J Herbert; J N Wilcox; K T Pham; R T Fremeau; M Zeviani; A Dwork; D R Soprano; A Makover; D S Goodman; E A Zimmerman
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

10.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.

Authors:  Z Lai; W Colón; J W Kelly
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

View more
  6 in total

Review 1.  Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.

Authors:  Laura Obici; Roberta Mussinelli
Journal:  Neurotherapeutics       Date:  2021-11-30       Impact factor: 6.088

Review 2.  Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.

Authors:  Jin-Beom Si; Bokyung Kim; Jin Hae Kim
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

3.  Structural basis for transthyretin amyloid formation in vitreous body of the eye.

Authors:  Irina Iakovleva; Michael Hall; Melanie Oelker; Linda Sandblad; Intissar Anan; A Elisabeth Sauer-Eriksson
Journal:  Nat Commun       Date:  2021-12-08       Impact factor: 14.919

4.  Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.

Authors:  Rodney H Falk; Mia Haddad; Crystal R Walker; Sharmila Dorbala; Sarah A M Cuddy
Journal:  JACC CardioOncol       Date:  2021-10-19

Review 5.  Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.

Authors:  Haruki Koike; Masahisa Katsuno
Journal:  Neurol Ther       Date:  2020-09-18

Review 6.  Ocular Involvement in Hereditary Amyloidosis.

Authors:  Angelo Maria Minnella; Roberta Rissotto; Elena Antoniazzi; Marco Di Girolamo; Marco Luigetti; Martina Maceroni; Daniela Bacherini; Benedetto Falsini; Stanislao Rizzo; Laura Obici
Journal:  Genes (Basel)       Date:  2021-06-22       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.